Biotech News

Iovance Biotherapeutics to Present at Upcoming Conference

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Conference / presentation

PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior

Related news

IOVAIovance Biotherapeutics, Inc.2026-10-28 23:00 EST

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

CRSPCRISPR Therapeutics2026-11-10 13:30 EST

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

KURAKura Oncology2026-11-13 17:33 EST

Kura Oncology to Participate in Two Investor Conferences in November

CRSPCRISPR Therapeutics2026-11-09 14:16 EST

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

Stock data

Close
7.31 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States